{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04023240",
            "orgStudyIdInfo": {
                "id": "IRB-52129"
            },
            "secondaryIdInfos": [
                {
                    "id": "VAR0195",
                    "type": "OTHER",
                    "domain": "OnCore"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "68-Ga-FAPI PET Imaging in Malignancy",
            "officialTitle": "68Ga-FAPI PET Imaging in Malignancy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "ga-fapi-pet-imaging-in-malignancy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-07-14",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12-14",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-07-15",
            "studyFirstSubmitQcDate": "2019-07-15",
            "studyFirstPostDateStruct": {
                "date": "2019-07-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to cancer activated fibroblasts. The PET scanner takes pictures that capture where the radioactive drug is \"lighting up\" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow doctors to identify smaller tumors than standard imaging.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nTo assess feasibility and biodistribution of PET imaging in malignancy using 68Ga-FAPI.\n\nOUTLINE:\n\nPatients receive 68Ga-FAPI intravenously (IV) and then undergo PET/CT approximately 1 hour later.\n\nAfter completion of study, patients are followed up at 24-72 hours."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "68Ga-FAPI PET/CT",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.",
                    "interventionNames": [
                        "Drug: 68Ga-FAPI",
                        "Procedure: Computed Tomography (CT) scan",
                        "Procedure: Positron Emission Tomography (PET) scan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "68Ga-FAPI",
                    "description": "68Ga-FAPI is quinoline based PET radiopharmaceutical.\n\n68Ga-FAPI is administered intravenously (IV)",
                    "armGroupLabels": [
                        "68Ga-FAPI PET/CT"
                    ],
                    "otherNames": [
                        "68-Ga-Fibroblast activation protein inhibitor (FAPI)"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography (CT) scan",
                    "description": "Participants will have a CT scan for attenuation correction and anatomic localization of PET data.",
                    "armGroupLabels": [
                        "68Ga-FAPI PET/CT"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography (PET) scan",
                    "description": "PET images will be acquired.",
                    "armGroupLabels": [
                        "68Ga-FAPI PET/CT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Feasibility of 68Ga-FAPI PET",
                    "description": "Feasibility of 68Ga-FAPI PET/CT imaging will be done to assess patients with malignancy. Feasibility will be measured using Likert scale (1-non diagnostic; 5-excellent; anything 3 or more is diagnostic). The study will be feasible if \\> 50% of scans will have a score of 3 or more",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient with current malignancy confirmed via pathology or imaging\n* Patient must be \\> 18 years old\n* Patient must be willing and able to provide written informed consent for the trial\n* Patient of reproductive potential will have a pregnancy test\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "19 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Risa Jiron",
                    "role": "CONTACT",
                    "phone": "650-736-1598",
                    "email": "rjiron@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Carina A Mari, MD",
                    "affiliation": "Stanford Universiy",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University Hospitals and Clinics",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21258",
                    "name": "Radiopharmaceuticals",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}